MedTrace Logo

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

NCT03698253 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-10-05

No results posted yet for this study

Summary

The survey is a retrospective study to evaluate the prognotic value of EGFR expression, KRAS mutations and tumor sideness in patients with metastatic colorectal cancer treated with regorafenib and FOLFIRI as a third- or fourth-line setting.

Conditions

Interventions

DRUG

Regorafenib

Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

GENETIC

UGT1A1 genotyping (TA6/TA6)

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2

GENETIC

UGT1A1 genotyping (TA6/TA7)

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2

GENETIC

UGT1A1 genotyping (TA7/TA7)

The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2

Sponsors & Collaborators

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    lead OTHER

Principal Investigators

  • Jaw-Yuan Wang, PhD · Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-01
Primary Completion
2018-06-01
Completion
2018-06-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698253 on ClinicalTrials.gov